Top Biotech companies

Pioneers enzymatic DNA synthesis on the benchtop with SYNTAX, the first commercial enzymatic DNA printer, letting labs make oligos on demand.

DNA Synthesis & Biofoundries · Series C $200M

DNA Synthesis & Biofoundries

Series C

$200M

HQ

CRISPR genome-editing platform built on chRDNA hybrid guides for higher-precision, multiplexed edits.

Gene & Genome Editing Platforms · IPO $304M

Gene & Genome Editing Platforms

IPO

$304M

HQ

Engineering-biology platform building ultra-compact CRISPR systems for in vivo gene editing and CRISPR-based diagnostics.

Gene & Genome Editing Platforms · Series D $150M

Gene & Genome Editing Platforms

Series D

$150M

HQ

Protein-discovery engine that finds and engineers novel compact CRISPR and editing enzymes for genetic medicines.

Gene & Genome Editing Platforms · Series C $73.9M

Gene & Genome Editing Platforms

Series C

$73.9M

HQ

Genetic-medicines platform that mines metagenomic sequence data to build a broad, proprietary gene-editing toolbox.

Gene & Genome Editing Platforms · IPO $93.8M

Gene & Genome Editing Platforms

IPO

$93.8M

HQ

Affordable open-source liquid-handling lab robots that automate pipetting and other benchtop workflows.

Cell Engineering & Bio-tools · Series C $200M

Cell Engineering & Bio-tools

Series C

$200M

HQ

Builds foundation models for biomolecular structure prediction and fully de novo antibody design.

AI Protein & Enzyme Design · Series B $130M

AI Protein & Enzyme Design

Series B

$130M

HQ

CAD-for-biology genetic design tools paired with engineered mammalian cell lines for therapeutics manufacturing.

Synthetic Genomics & Data Storage · Series B $175M

Synthetic Genomics & Data Storage

Series B

$175M

HQ

Antheia uses engineered yeast fermentation to manufacture plant-inspired pharmaceutical ingredients such as thebaine without growing the source crops.

Builds large language models for protein design and created OpenCRISPR-1, the first AI-generated gene editor.

AI Protein & Enzyme Design · Series B $106M

AI Protein & Enzyme Design

Series B

$106M

HQ

Molecular-engineering platform that builds CRISPR enzymes from the ground up and licenses them for in vivo gene editing.

Gene & Genome Editing Platforms · Series B $100M

Gene & Genome Editing Platforms

Series B

$100M

HQ

Uses AI to engineer AAV capsids as improved gene-delivery vectors, licensing designs to major pharma.

AI Protein & Enzyme Design · Series A $100M

AI Protein & Enzyme Design

Series A

$100M

HQ

Cloud bioreactors and Console software that let teams run and monitor bioprocess development experiments remotely.

Cell Engineering & Bio-tools · Series C

Cell Engineering & Bio-tools

Series C

—

HQ

Allonnia engineers microbes and enzymes to break down pollutants and recover critical minerals from waste streams.

Generative-AI protein-engineering SaaS that lets any lab design and optimize proteins without deep computational expertise.

AI Protein & Enzyme Design · Series B $73M

AI Protein & Enzyme Design

Series B

$73M

HQ

Builds an ethically-sourced global biodiversity database, BaseData, to fuel generative protein foundation models.

AI Protein & Enzyme Design · Series A $20M

AI Protein & Enzyme Design

Series A

$20M

HQ

Builds fully recoded synthetic genomes that reprogram the genetic code so engineered cells can produce proteins and biopolymers with chemistries natural biology cannot make.

Synthetic Genomics & Data Storage · Series A $58M

Synthetic Genomics & Data Storage

Series A

$58M

HQ

High-throughput cell-line engineering to boost yields for viral-vector and gene-therapy manufacturing.

Cell Engineering & Bio-tools · Series A $55M

Cell Engineering & Bio-tools

Series A

$55M

HQ

Cloud bioinformatics platform for orchestrating and analyzing large biological datasets without code.

Cell Engineering & Bio-tools · Series A $28M

Cell Engineering & Bio-tools

Series A

$28M

HQ

Roebling (formerly Synonym) builds software and financing infrastructure to plan, model, and fund biomanufacturing and other industrial process facilities.